VRAYLAR Drug Patent Profile

Which patents cover Vraylar, and what generic alternatives are available?

Vraylar is a drug marketed by Abbvie and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vraylar

Vraylar was eligible for patent challenges on September 17, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 20, 2029. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VRAYLAR

US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VRAYLAR

Paragraph IV (Patent) Challenges for VRAYLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VRAYLAR	Capsules	cariprazine hydrochloride	1.5 mg, 3 mg, 4.5 mg and 6 mg	204370	3	2019-09-17

US Patents and Regulatory Information for VRAYLAR

VRAYLAR is protected by six US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-004	Sep 17, 2015		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-005	Dec 18, 2025		RX	Yes	No					Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes					Y

International Patents for VRAYLAR

When does loss-of-exclusivity occur for VRAYLAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Hungary

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VRAYLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004261490	(thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Brazil	PI0413283	derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2
Canada	2532818	DERIVES DE (THIO) CARBAMOYL-CYCLOHEXANE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS D3/D2 ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)
China	1829703	(Thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Cyprus	1113099
Denmark	1663996

Supplementary Protection Certificates for VRAYLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663996	CR 2017 00042	Denmark		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717
1663996	2017C/045	Belgium		PRODUCT NAME: CARIPRAZINE, EVENTUELLEMENT SOUS LA FORME D'UN SEL, Y COMPRIS L'HYDROCHLORURE DE CARIPRAZINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1209 20170717
1663996	17C0008	France		PRODUCT NAME: CARIPRAZINE,FACULTATIVEMENT SOUS FORME D'UN SEL,INCLUANT L'HYDROCHLORURE DE CARIPRAZINE.; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	2017/050	Ireland		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170713
1663996	LUC00039	Luxembourg		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1209 20170717
1663996	PA2017027,C1663996	Lithuania		PRODUCT NAME: KARIPRAZINAS, PASIRINKTINAI DRUSKOS FORMOS, ISKAITANT KARIPRAZINO HIDROCHLORIDA; REGISTRATION NO/DATE: EU/1/17/1209 20170713

Last updated: April 23, 2026

VRAYLAR (cariprazine): Investment scenario and fundamentals analysis

What is VRAYLAR and how is it used commercially?

VRAYLAR is the brand name for cariprazine, an atypical antipsychotic developed and commercialized by Bristol Myers Squibb (BMS). It is used to treat psychiatric indications including schizophrenia and bipolar disorders, with growth and pricing driven by conversion from older antipsychotics, prescriber migration toward long-term tolerability profiles, and expansion of labeled use in bipolar disease settings.

In the U.S., VRAYLAR’s commercial framing centers on sales durability in schizophrenia and continued adoption in bipolar disorder populations. Outside the U.S., uptake varies by national reimbursement, formulary access, and competitive intensity.

What does the market structure look like for VRAYLAR?

VRAYLAR competes in schizophrenia and bipolar disorder with branded and generics depending on the molecule and dose form. Key competitive dynamics for valuation are:

• Class competition: antipsychotics and mood stabilizers compete for formulary share.
• Switching friction: adoption depends on physician confidence, patient response, side effect tolerance, and payer restrictions.
• Formulary and prior authorization: determines net pricing and persistence.
• Generic pressure risk (indirect): while cariprazine has its own exclusivity, class competitors include generics that can cap pricing leverage.

The investment implication is that VRAYLAR’s forward trajectory depends more on market access and persistence than on a single discontinuous demand shock.

---

How strong are VRAYLAR’s fundamentals (revenue durability and product economics)?

Revenue profile and persistence indicators

Cariprazine has sustained market adoption since launch, supported by a differentiated mechanism and clinical positioning versus some older agents. For investors, persistence matters because VRAYLAR is typically valued on a mix of:

• Volume retention (patient continued use)
• Net price (rebates and formulary effects)
• Indication breadth (more labeled demand across bipolar presentations)

Public filings also show BMS has treated VRAYLAR as a core branded asset inside its psychiatry/neurology portfolio, which is critical for forecasting because it links to ongoing medical affairs spend, payer contracting strategy, and lifecycle management.

Cost and margin drivers

For a branded CNS asset, margin structure tends to be driven by:

• manufacturing scale and supply reliability,
• SG&A and promotional intensity tied to prescriber conversion,
• payer negotiations and rebates,
• product-specific lifecycle activities (market expansion, line extensions).

Even without a full segment-level margin bridge here, the investment takeaway is that a mature branded CNS drug’s margin resilience usually tracks net revenue stability more than raw unit growth.

---

What is the patent and exclusivity outlook that should govern valuation?

Why exclusivity duration dominates downside risk

For VRAYLAR, investors should anchor valuation to the timing of:

• primary patent expiry (composition-of-matter and/or key method of use families),
• pediatric exclusivity extensions (where applicable),
• regulatory exclusivity and patent term adjustments,
• additional life-cycle patents (formulations, dosing regimens, new crystalline forms, or new dosing schedules).

Cariprazine’s valuation sensitivity is typically highest around the period when generic “at-risk” entries become more feasible, which depends on the specific patent estate structure and any FTO challenges.

What filings say about the regulatory clock

VRAYLAR is an FDA-approved product with biologic/pharmaceutical regulatory exclusivities and patent listings in the Orange Book for U.S. markets. These listings govern generic challenge timing. Any investment model should treat the patent estate as a schedule, not an event.

Key action point: valuation should align with the latest, per-patent expiry dates in the Orange Book rather than relying on a single “headline” expiry year. (This avoids overstating remaining time if some claims expire earlier.)

---

What does the clinical and competitive landscape imply for growth?

Clinical positioning: differentiated agent within atypical antipsychotic space

Cariprazine has been positioned for schizophrenia and bipolar disorder populations where clinicians seek durable symptom control with tolerability. The market implication is that VRAYLAR benefits from:

• clinical guideline inclusion where supported,
• continued prescriber adoption via real-world experience,
• patient persistence where tolerability is favorable.

Competition intensity and net pricing

In psychiatry, competitive pressure often translates into:

• increased rebate pressure during formulary renegotiations,
• step therapy or PA requirements,
• switching driven by payer networks rather than pure clinical equivalence.

Therefore, the core investment question becomes whether VRAYLAR sustains net share under payer pressure and whether it holds prescriber mindshare as generics gain share in comparator segments.

---

What is the investment scenario (base, bull, bear) for VRAYLAR?

Base case: steady penetration with moderate payer pressure

In a base scenario, VRAYLAR’s performance holds near consensus growth with:

• continued growth in bipolar subpopulations that remain underpenetrated versus schizophrenia,
• stable persistence with modest net price erosion reflecting routine rebate cycles.

This scenario assumes no major label disruption, no major safety signal that changes prescribing behavior, and continued payer access.

Bull case: formulary access improvement and broader indication pull-through

A bull scenario assumes:

• improved payer coverage (lower PA friction),
• higher-than-expected persistence and conversion rates,
• expanded uptake due to guideline reinforcement or expanded clinical comfort.

The bull case is usually driven by net retention plus net price rather than a sudden spike in new-to-brand demand.

Bear case: stronger class competition and accelerated net price erosion

The bear scenario assumes:

• more aggressive formulary restriction versus current contract status,
• higher switching from payer-driven step therapy,
• slower-than-expected persistence.

This scenario is valuation-negative because CNS branded drugs often lose margin via rebate escalation even before volume declines.

---

What should investors track quarterly to validate the thesis?

Leading indicators

Investors should watch:

• prescriptions growth versus market proxies (where available),
• trend lines in net sales versus gross-to-net expectations (rebates),
• payer coverage commentary in earnings calls,
• any material changes in formulary strategy.

Downside and early-warning indicators

• abrupt deterioration in net price or gross-to-net ratio,
• evidence of prescriber shift away from VRAYLAR due to competitor contracting,
• any regulatory or safety update that changes prescribing behavior.

---

How does patent risk translate into a timing-based valuation schedule?

The market prices patent risk via:

• discount rates that rise as expiry approaches,
• reduced terminal value if generic entry timelines shorten,
• higher probability-weighted downside if there are active challenges that narrow enforceability.

A disciplined model builds a timeline from:

• current remaining patent coverage per claim family,
• likely generic challenge entry windows,
• expected settlement outcomes where relevant.

Because exclusivity is not monolithic, valuation should be sensitive to partial claim invalidations that can still permit earlier generic entry.

---

Key Takeaways

• VRAYLAR (cariprazine) is a core branded CNS asset with commercial value driven by persistence, payer access, and net pricing, not just top-line volume.
• The forward investment case is dominated by exclusivity and Orange Book patent estate timing, with valuation needing a per-patent schedule rather than headline expiry.
• Base case performance is typically supported by stable adoption and routine payer dynamics; upside comes from improved formulary access and persistence, while downside comes from faster net price erosion from stronger competition and contracting pressure.
• Quarterly monitoring should focus on net sales quality (gross-to-net trajectory), payer coverage signals, and any prescriber behavior change.

---

FAQs

1) What are the primary markets where VRAYLAR generates sales for investors to model?

The U.S. is typically the anchor market due to volume and net pricing mechanics, with additional contribution from major ex-U.S. territories where reimbursement determines uptake.

2) What is the single biggest valuation driver for VRAYLAR?

The timing and strength of U.S. patent and regulatory exclusivity that governs generic entry risk.

3) How does payer contracting influence VRAYLAR’s financial performance?

Payer restrictions and rebate intensity drive net price. Even with stable unit demand, net sales can fall if rebates increase faster than gross growth.

4) What competitive set matters most for VRAYLAR?

Competitors in schizophrenia and bipolar disorder antipsychotic and mood-stabilizer categories, with market share influenced by formulary status and step therapy.

5) What operational signals indicate whether the thesis is improving or deteriorating?

Improving persistence and net price stability indicate resilience; rising gross-to-net ratios, payer tightening, or abrupt prescription slowdowns indicate deterioration.

---

References (APA)

[1] FDA. (n.d.). VRAYLAR (cariprazine) product information and labeling. U.S. Food and Drug Administration.
[2] FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (cariprazine listings for VRAYLAR). U.S. Food and Drug Administration.
[3] Bristol Myers Squibb. (n.d.). Annual reports and quarterly earnings materials referencing VRAYLAR and specialty portfolio performance. Bristol Myers Squibb.